A new radioactive treatment for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with prostate cancer that has spread and is not responding to hormone therapy.
- Your PSMA PET scan must show that the cancer is visible (positive).
- You must have already tried at least one newer hormone therapy (like enzalutamide or abiraterone) or a taxane chemotherapy, or you cannot tolerate/refuse chemo.
- You should be generally well (able to do daily activities) and have a life expectancy of at least 6 months.
- Your liver, kidney, and blood test results need to be within acceptable limits.
- You must not have had major surgery or a serious infection in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new radioactive treatment, terbium-161, for men with advanced prostate cancer that has stopped responding to other treatments. It aims to see if this treatment can target and kill cancer cells.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.